- Mikael Dohlsten, M.D., Ph.D., To Succeed As President, Wyeth Research -
MADISON, N.J., April 30 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced that Robert R. Ruffolo, Jr., Ph.D., 58, will retire as President, Wyeth Research and Senior Vice President, Wyeth, later this year. He will be succeeded by Mikael Dohlsten, M.D., Ph.D.
Dr. Ruffolo joined Wyeth in November 2000 and has been responsible for all pharmaceutical research and development (R&D) for the Company, including discovery, drug safety and metabolism, chemical and pharmaceutical development, clinical R&D and research operations.
"Bob Ruffolo has been the driving force of our R&D progress, establishing Wyeth as one of the research leaders in the pharmaceutical industry," says Bernard Poussot, Wyeth's President and Chief Executive Officer. "His legacy will be our pipeline, recognized as one of the industry's most innovative. Bob has helped position our company for future growth through robust research and development programs in oncology, women's health, vaccines, inflammation, cardiovascular and metabolic diseases and neuroscience -- led by our multi-platform effort in Alzheimer's."
Throughout his 31-year career in the pharmaceutical industry, Dr.
Ruffolo's work has been recognized with a number of prestigious awards. In
March, he was recognized by the Pharmaceutical Research and Manufacturers
of America (PhRMA) with the 2008 Discoverer's Award for his efforts in the
discovery and development of Coreg(R) while at GlaxoSmithKline. The Wyeth
Research and Development Executive Team (RADEX), formed and chaired by Dr.
Ruffolo, won the 2006 Scrip Award for Management Team of the Year. In 2005,
he won the George B. Koelle Award for Scientific Excelle
Copyright©2008 PR Newswire.
All rights reserved